Home LiteratureArticle Details
PMID: 9932965 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Mortality cancer risk in parkinsonian patients: a population-based study.

Neurology ·Vol. 52 ·No. 2 ·1999-01-15 ·Pages 395-8

Vanacore N, Spila-Alegiani S, Raschetti R, Meco G

Abstract

Cancer mortality in a population-based cohort of 10,322 parkinsonian patients (448 deaths observed during 1987 to 1994) was compared with that of the Italian province of Rome using the standardized mortality ratio (SMR). The overall cancer mortality risk was lower in this cohort than in the reference population (SMR, 56; 95% CI, 51 to 61). This reduction included most cancer sites as well as both smoking-related (SMR, 51; 95% CI, 42 to 60) and nonsmoking-related cancers (SMR, 58; 95% CI, 52 to 65). The observed reduction in cancer mortality risk in this cohort cannot be explained entirely by the hypothesis that smokers are less likely to develop PD.

MeSH Terms
Adult Age Distribution Aged Aged, 80 and over Antiparkinson Agents/therapeutic use Female Humans Levodopa/therapeutic use Male Middle Aged Neoplasms/complications,mortality Parkinson Disease/complications,drug therapy Poisson Distribution Retrospective Studies Rome/epidemiology Selegiline/therapeutic use
Chemicals
Antiparkinson Agents Selegiline Levodopa
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Vanacore N
Department of Neurological Sciences, La Sapienza University, Rome, Italy.
Spila-Alegiani S
Raschetti R
Meco G
Article Info
Journal
Neurology
Abbr.
Neurology
ISSN
0028-3878
Published
1999-01-15
Pages
395-8
Language
English
Region
United States
NLM ID
0401060
Subset
IM
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com